Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses-Reference-Cited by-同舟云学术

Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses

Published:2022 Issue: Volume:3 Page:100080
ISSN:2590-2571
Container-title:Current Research in Pharmacology and Drug Discovery
language:en
Short-container-title:Current Research in Pharmacology and Drug Discovery

Author:

S Lakshmi^ORCID,A Shanitha,Dv Shiny^ORCID,Bs Rahul,R Saikant^ORCID,Sharaf Shehna^ORCID,Sa Abi,G Rajmohan

Publisher

Elsevier BV

Subject

General Medicine

Reference98 articles.

1. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies;Abbasi-Radmoghaddam;Mol. Divers.,2021

2. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: a meta-analysis;Adomaityte,2008

3. PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy;Agrawal;Nanomedicine,2016

4. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer;Allred;Breast Cancer Res.,2004

5. The PARP superfamily;Amé;Bioessays,2004

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antitumor Activity of Antiestrogen-Cytostatics and Their Binding Affinity with Estrogen Receptors;Pharmaceutical Chemistry Journal;2024-01

2. A comparative study of Bazedoxifene, Exemestane, Fulvestrant, Raloxifene, Tryprostatin A, and Vorinostat compounds as potential inhibitors against breast cancer through molecular docking, and molecular dynamics simulation;Chinese Journal of Analytical Chemistry;2023-10

3. Design, synthesis and evaluation of the anti-breast cancer activity of 1,3-oxazolo[4,5-d]pyrimidine and 1,3-oxazolo[5,4-d]pyrimidine derivatives;RSC Medicinal Chemistry;2023